What is the real feedback on the efficacy of erdafitinib?

Erdafitinib is a selective fibroblast growth factor receptor (FGFR) inhibitor, mainly used to treat patients with advanced or metastatic urothelial cancer (bladder cancer) carrying FGFR2 or FGFR3 gene mutations. As the first approved targeted drug targeting FGFR gene mutations, feedback on its efficacy has attracted widespread attention.

Based on patient feedback, the efficacy of erdafitinib in specific populations is considered to be clinically significant, especially providing a new treatment path for patients who have failed traditional treatments (such as platinum-containing chemotherapy). Feedback from patients shows that some people have stabilized their condition or experienced tumor shrinkage after receiving treatment, especially those with clear genetic mutations, who have a relatively high response rate. It is worth noting that the mechanism of action of this drug is relatively precise, so it is not suitable for groups where FGFR gene mutations have not been detected.

Judging from real-world treatment experience, patients generally believe that erdafitinib is well tolerated, but it is also accompanied by some common side effects of targeted drugs, such as hyperphosphatemia, eye discomfort, rash, and gastrointestinal reactions. Therefore, blood phosphorus levels need to be monitored regularly during treatment, and corresponding dose adjustments or supportive treatments are required. In addition, some patients may experience short-term fluctuations in adverse reactions at the beginning of treatment, but they can gradually stabilize after optimization of drug dosage. For patients whose disease has progressed after multiple lines of therapy, erdafitinib still shows some potential to delay disease progression, which is particularly critical in advanced patients with limited traditional treatment options.

Although there are differences in individual efficacy, in the evaluation of this drug by the international oncology community, erdafitinib is considered an important representative of precision medicine in the field of urinary system tumors. Its efficacy depends on precise genetic screening, appropriate medication management, and a comprehensive grasp of individual differences.

Reference materials：https://www.balversa.com/